A Study of Sacituzumab Govitecan (IMMU-132) in Platinum-resistant Ovarian Cancer Patients
Clinical trial NCT06028932 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06028932
- Sponsor
- Yale University
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-01-08
- Primary completion
- 2026-11-01
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.